Avalon GloboCare Expands IP Portfolio; Files 16 new patent applications

0

Avalon GloboCare Corp.

Co-inventors are leading international universities and cell therapy developers

Patent applications cover three types of cell therapies and related technologies

FREEHOLD, NJ, April 27, 2022 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cellular technologies and therapies, today announced that the company has jointly filed 16 patent applications, co-invented with key strategic partners, including a US university among top 5, a leading teaching and research center in Europe, as well as a leading multinational developer of cell therapies in the field of oncology. Patents have been filed with the United States Patent and Trademark Office (USPTO), China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries .

The new intellectual property covers three main families of patents:

  • Engineering and biofabrication of novel chimeric antigen receptor (CAR) T cells linked to the mRNA-based Flash-CARTM cell therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently in the development stage of the process to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials. .

  • Antibody-derived soluble cytokine/chemokine decoy receptors using the QTY protein design, with potential applications including mitigating the “cytokine storm” associated with COVID-19 and administration of cellular immunotherapy, as well as the expansion of the range of therapeutic targets that can be addressed by CAR T cell therapies.

  • Novel fusion proteins derived from S-layer coated emulsomy (SLET) technology for mucosal vaccine development, which are designed to elicit robust protective immune responses at sites prevalent in pathogen infection. The SLET platform provides a “molecular GPS system” to guide the traffic and delivery of a payload to a targeted destination within the body.

“These latest patent applications strengthen and expand our strong intellectual property portfolio, both in the United States and internationally,” said David Jin, MD, Ph.D., President and CEO of Avalon. GloboCare. “We are particularly honored to partner with several of the world’s leading researchers and academic institutions in the field of cell therapy, as co-inventors of the technologies. We believe these patent applications will expand our geographic intellectual property protection and are timed to maximize patent life for decades to come. These patents are part of our core competencies in the areas of CAR-T, QTY protein design and S-layer technologies, strengthening our leadership position in immuno-oncology and cellular medicine. Collectively, we believe that each of these patents covers therapies and technologies that target broad addressable markets. They are all backed by strong preclinical data as we move rapidly towards first-in-human clinical trials. »

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading, vertically integrated, clinical-stage CellTech bio-developer dedicated to advancing and empowering innovative and transformative immune effector cell therapy, exosome technology , as well as diagnostics and therapies related to COVID-19. Avalon also provides strategic consulting and outsourcing services to facilitate and enhance its customers’ growth and development, as well as competitiveness in the healthcare and cellular technology industry markets. Through its subsidiary structure with a unique integration of verticals ranging from innovative R&D to automated biomanufacturing and accelerated clinical development, Avalon is establishing a leading role in the areas of cellular immunotherapy (including CAR-T/NK ), exosome technology (ACTEX™) and therapeutic regeneration. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare developments, please follow our twitter at @avalongc_avco

Forward-looking statements
Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that is not directly related to historical or current fact. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, results and results may differ materially due to broader factors, including (but not limited to) general industry and market conditions and growth rates, economic conditions and changes in government and public policy. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and those views are subject to change. However, while the Company may choose to update these forward-looking statements at some point in the future, the Company expressly disclaims any obligation to do so. These forward-looking statements should not be taken to represent the views of the Company as of any date subsequent to the date of the press release.

Contact information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
[email protected]

Investor Relations:
Crescendo Communications, LLC
Such. : (212) 671-1020 ext. 304
[email protected]

Share.

Comments are closed.